P138: An atypical and complex BCR-ABL translocation in a chronic myeloid leukemia patient and its response to TKI therapy

Methods: Comparison of HCC and matched normal tissue gene expression was performed with the UALCAN and GEPIA online graphical user interfaces.Correlation between SLCO gene expression and patient survival was evaluated with OncoLnc.SLCO genetic alterations in HCC were also explored using cBioPortal.Results: Expression of SLC22A1 is significantly down-regulated in the clinic-pathological characteristics (cancer stages, tumor grade and nodal metastasis status) examined in HCC patients compared to normal counterparts.Clinically, low expression of SLC22A1 is correlated with shorter overall survival in HCC patients, with a log-rank p-value of 0.00007.Top of Form Analysis of the TCGA Liver Hepatocellular Carcinoma dataset (TCGA's Pan-Cancer Atlas) revealed a low amplification and deep deletion frequency in HCC (0.54% vs 1.61%).Conclusion: SLC22A1 are highly expressed in the liver and play key roles in many liver diseases.In HCC patients, downregulation of SLC22A1 expression has been observed.SLC22A1 expression levels may also serve as prognostic predictive markers in HCC patients.